• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to variants of CC chemokines that carry at least two mutations in the cationic site of the 40 'loop and exhibit reduced GAG-binding activity compared to wild type molecules. In particular, these mutated chemokines have been found to be effective in the treatment of multiple sclerosis or other demyelinating diseases. Triple variants of RANTES are compounds with optimal results.
    公开号:KR20030034238A
    申请号:KR10-2003-7004599
    申请日:2001-10-03
    公开日:2003-05-01
    发明作者:아만다 프로우드풋트；티모시엔.씨. 웰스；마리에 코스코-빌보이스
    申请人:어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.；
    IPC主号:
    专利说明:

    CHEMOKINE MUTANTS IN THE TREATMENT OF MULTIPLE SCLEROSIS}
    [2] Chemokines are a family of small pro-inflammatory cytokines with leukocyte chemotaxis and activation properties. Depending on the position of the first conserved cysteine, the chemokine family can be divided into CC, CXC and CX 3 -C chemokines (Baggiolini M. et al., Adv Immunol. 1994, 55: 97-179; Baggiolini M. et al., Annu Rev Immunol. 1997, 15: 675-705; Taub D. et al. Cytokine Growth Factor Rev. 1996, 7 (4): 355-76).
    [3] Many C-X-C chemokines, such as interleukin-8 (IL-8), act on monocytes, lymphocytes, eosinophils, basophils, NK cells, dendritic cells.
    [4] The NH 2 -terminal domain of the chemokine is involved in receptor binding and the NH 2 -terminal processing can activate or completely inactivate the chemokine.
    [5] N-terminal variants of the synthetic CC chemokines were tested for their activity as naturally occurring forms of inhibitors or antagonists. MCP-1, MCP-2 and RANTES deleted from 8 to 9 NH 2 -terminal amino acids are inert to monocytes and useful as receptor antagonists (Gong JH et al., J Exp Med. 1995, 181 (2): 631-40; Gong JH et al., J Biol Chem. 1996, 271 (18): 1052-7).
    [6] Stretching RANTES with one methionine almost completely inactivates the molecule, and Met-RANTES acts as an antagonist to actual RANTES (Prudfoot AE et al., J Biol Chem. 1996 Feb 2: 271 (5)- 2599-603).
    [7] WO 99/16877 discloses amino-terminated truncated RANTES, in which NH 2 -terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3 or 1-4 of naturally occurring RANTES are deleted and retain chemokine antagonistic activity, CDNA sequences that encode, and their use in the treatment and / or prevention of diseases in which antagonistic activity of chemokine effects is required. RANTES (3-68) is the preferred truncated chemokine antagonist.
    [8] Although the chemotactic activity of RANTES and CC chemokines is generally studied in relation to specific cell membrane receptors, RANTES is a highly variable branched glycofunctional group, commonly referred to as proteoglycans (PGs) and post-translationally added to some proteins. It also interacts with glycosaminoglycans (GAG). These proteins are present in the cell membrane, extracellular matrix, and bloodstream, where separate GAGs may also be present.
    [9] Interaction with GAGs is a common feature for many cell-signaling soluble molecules (interleukin, growth factor). PG or isolated GAG can form complexes with soluble molecules within the scope of blocking proteolysis in the extracellular environment. GAGs have been shown to facilitate the accurate presentation of cell signaling molecules to specific receptors and thus the regulation of target cell activation.
    [10] In the case of chemokines, the enrichment to a fixed gradient at the site of inflammation, and thus its interaction with cellular receptors and their activation state, appears to be regulated by different forms of GAG (Hoogewerf AJ et al., Biochemistry 1997, 36 (44): 13570-8). Thus, such interactions may result in inflammatory diseases (Schwarz MK and Wells TN, Curr Opin Chem Biol. 1999, 3 (4): 407-17) and HIV infection (Burns JM et al., Proc Natl Acad Sci USA 1999, 96 ( 25): 14499-504) to represent a therapeutic approach.
    [11] Structural needs and functional effects of GAG-RANTES interactions are being studied in various models. RANTES binds to GAG of human umbilical vein endothelial cells (HUVEC) at micromolar concentrations with higher affinity and specificity than other chemokines such as MCP-1, IL-8 or MIP-1alpha. This interaction appears to depend on the length of the GAG and other variables such as N- and O-sulfation, not just electrostatics (Kuschert GS et al., Biochemistry 1999, 38 (39): 12959 -68). GAG-deficient cell lines can also bind chemokines, but the presence of cell surface GAGs significantly enhances their activity at the receptor at low concentrations (Ali S et al., J Biol Chem 2000, 275 (16): 11721-7). Other experiments have shown that GAG, in particular heparin sulfate, promotes the interaction between RANTES and macrophage cell surfaces and consequently inhibits HIV infection, which may have been associated with the RANTES antiviral effect of these cells with poor expression of heparin sulfate. Consistent with known resistance (Oravecz T, et al., J Immunol. 1997, 159 (9): 4587-92).
    [12] Soluble GAGs compete with cell membrane GAGs and are specific inhibitors of RANTES-induced activation surfaces (Appay V, et al., Int Immunol 2000, 12 (8): 1173-82) or inhibitors of HIV infection (Burns) JM et al., Proc Natl Acad Sci USA 1999, 96 (25): 14499-504).
    [13] Some structure-function studies have attempted to identify the RANTES domain responsible for interacting with GAG because the traditional consensus sequence (BBXB, where B is a basic residue and X is any residue) is too comprehensive. . Epitope-mapping studies were conducted using monoclonal antibodies that were able to block both the viral mediated antiviral effects and the recruitment of intracellular calcium to recombinant human RANTES (Burns JM et al .; J Exp. Med. 1998, 188 (10): 1917-27). This approach defines residues 55-66 required for both this activity and GAG interactions, and the interaction mediated by canonical receptors, as shown in studies of RANTES variants with GAG interactions showing modified aggregation characteristics. It may claim to have a complementary or different function than that (Appay V et al., J Biol Chem 1999, 274 (39): 27505-12).
    [14] Regions 55-66, representing the C-terminal alpha-helix segment, are homologous to the GAG-binding domain of other chemokines such as IL-18 (Witt DP and lander AD, Curr. Biol. 1994, 4 (5): 394- 400) and a cationic site (KKWVR) containing lysine and arginine. This binding region differs from the binding site for the cell receptor located at the N-terminus (Pakianathan DR et al., Biochemistry 1997, 36 (32): 9642-8) and possesses some residues involved in the aggregation of RANTES monomers. However, this disaggregating mutation does not appear to affect the interaction with GAG (Czaplewski LG et al., J. Biol. Chem. 1999, 274 (23): 16077-84; WO 98/13495) .
    [15] RANTES is MIP-1α (Koopmann W and Krangel MS, J. Biol. Chem. 1997, 272 (15): 10103-9) and MIP-1β (Koopmann W et al., J Immunol. 1999, 163 (4): Have different cationic sites (RKNR) at residues 44-47 conserved in the GAG binding domain of other chemokines such as 2120-7).
    [16] Human RANTES variants carrying a single mutation at these cationic sites have been disclosed as RANTES antagonists with potential therapeutic potential in the treatment of HIV infection and inflammatory or allergic diseases (WO 93/33989).
    [17] It has also been shown that only triple variants of RANTES where three residues at positions 44, 45, 46 are substituted with alanine lose GAG-binding capacity (A. Proudfot et al., Chemokine Gordon Conference, Session I, July 24 th 2000).
    [1] The present invention relates to variants of CC chemokines that carry at least two mutations in the 40 'loop and exhibit reduced GAG-binding activity compared to wild-type molecules: such mutated chemokines are multiple sclerosis and / or other demyelinating It has been shown to be effective in the treatment of demyelinating diseases.
    [43] 1 shows the alignment of some typical CC chemokines arranged at the level of a 40 'loop. Protein segments and cationic sites corresponding to GAG-binding motifs are boxed.
    [44] 2 shows a genetic map of plasmids used to clone wild type RANTES and variants thereof according to the examples.
    [45] 3 shows the results of a competitive binding assay of [ 125 I] -RANTES and variants by heparin in the heparin bead assay.
    [46] 4 depicts the competitive equilibrium binding analysis of RANTES and triple 40 ′ RANTES variants.
    [47] 5 depicts the induction of monocytes and T cell chemotaxis by RANTES and triple 40 ′ and 50 ′ RANTES variants.
    [48] 6 shows inhibition of peritoneal cell recruitment by triple 40 ′ RANTES variants.
    [49] FIG. 7 shows inhibition of RANTES induced peritoneal cell recruitment by truncated triple 40 ′ RANTES (3-68) variants produced in Pichia pastoris .
    [50] 8 shows inhibition of MIP-1β induced peritoneal cell recruitment by MIP-1β triple 40 'variant (K45AR46AK48A).
    [51] 9 shows inhibition of MIP-1α induced peritoneal cell recruitment by triple MIP-1α variants (R18A-R46A-R48A).
    [52] 10 shows inhibition of thioglycollate induced cell recruitment by triple 40 ′ RANTES variants.
    [53] FIG. 11 shows inhibition of the development of experimental autoimmune encephalomyelitis by all-40 ′ RANTES triple variants according to the present invention.
    [18] CC chemokines comprising at least two mutations at the cationic site of the so-called "40 'loop" have been found to be effective in the treatment of multiple sclerosis and / or other demyelinating diseases. This site represents GAG-binding motifs conserved in CC chemokines (eg, RANTES, MIP-1 alpha and MIP-1 beta, MIP-3, MIP-4, HCC1, 1309, MCP-2). All these chemokine variants show reduced GAG-binding activity compared to the corresponding wild type molecule.
    [19] The region in which at least two mutations are present in the present invention, the so-called 40 'loop, is indicated for a number of CC chemokines in FIG. 1. In particular, the RANTES triple variant with three basic residues substituted with alanine at positions 44, 45, 47 has been found to be active in animal models for the treatment of multiple sclerosis. This RANTES triple variant showed a dose-related effect in the murine EAE model and comparable efficacy to baseline treatment of recombinant IFN-beta. Similar results were found in truncated RANTES triple variants in which three residues at positions 44, 45, 47 were substituted with alanine and the first two N-terminal amino acids were deleted. This truncated RANTES variant (having amino acid sequence SEQ ID NO: 3) is another novel object of the present invention.
    [20] MIP-1α triple variant R18A-R46A-R48A (Koopman W and Krangel MS., J Biol Chem. 1997, 272 (15): 10103-9) and MIP-1β triple 40 ′ variant K45A-R46A- already known and herein Similar results were obtained for the triple variants of MIP-1alpha and MIP-1beta identified by K48A (Laurence JS Biochemistry 2001, 40: 4990-4999).
    [21] "Reduced GAG-binding activity" means that the variants of the invention have a lower binding capacity to GAG, ie each of these variants has a lower rate of GAG (e.g., heparin sulfate) compared to the corresponding wild-type molecule. It means to combine.
    [22] Variants of human RANTES are more preferred, wherein the three basic amino acids are replaced with other amino acids at positions 44, 45, 47 of the wild type molecule. Such residues may be substituted with small, aliphatic, non-polar or weakly polar residues such as Ala, Ser, Thr, Pro, Gly. Alanine (Ala) is preferred.
    [23] RANTES variants that have been found to be particularly effective in the treatment of MS have the amino acid sequences reported in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
    [24] Another object of the present invention is the use of the aforementioned chemokine variants for producing a pharmaceutical composition for treating multiple sclerosis and / or other demyelinating diseases.
    [25] Multiple sclerosis (MS) is a progressive, progressive CNS disease characterized by spreading patches of demyelination in the brain and spinal cord, resulting in multiple neurological symptoms and signs of multiple repetition and exacerbations. Merck Mannual, sixteenth edition).
    [26] Although the cause is unknown and is believed to be due to immunological abnormalities, no clue suggests specific mechanisms. Probable causes include infection with slow or latent viruses and myelination by enzymes. IgG is commonly elevated in CSF, and elevated titers are associated with various viruses, including measles. The significance of this finding and the association between HLA allotypes and altered T cell numbers is not clear because the evidence is somewhat conflicting. Increased family incidence suggests genetic susceptibility; Women are a bit more at risk than men. There seems to be an environmental factor. Although the age at onset usually ranges from 20 to 40 years, MS correlated with the local environment in which patients live for the first 15 years. Migration after age 15 does not change this risk.
    [27] Myelin plaques or cell populations showing oligodendrocyte destruction and perivascular inflammation are spread throughout the CNS, mainly in the white matter, with lateral and posterior fibrous ends (especially cervical and spinal regions), optic nerves, and pericardial ventricle being preferred. The tract is also affected in the midbrain, pons, and cerebellum, and gray matter may be affected in the cerebrum and cord.
    [28] Cell bodies and axons are preserved, especially in early lesions. Axons can then be destroyed, especially in long neuronal lines, and gliosis gives this neuronal "sclerotic" appearance. Early and late lesions may be found at the same time. Around the plaque, chemical changes were observed in the lipid and protein composition of myelin.
    [29] The disease is characterized by various diseases and findings of CNS dysfunction that continually repeats alleviation and exacerbation.
    [30] Magnetic resonance imaging (MRI) is the most sensitive imaging technique; This can show many plaques. Lesions can also be seen on contrast-enhanced tomography.
    [31] Therapeutic advances in multiple sclerosis (MS) are delayed due to a lack of understanding of the etiology of the disease. Major obstacles to development in experience-based treatment include the wide variety of MS processes, the long-term nature of the most important outcome measures, and the absence of objective markers of therapeutic effects (especially in the short term).
    [32] The pathogenesis of MS is still uncertain, but natural history is constantly being studied. Objective outcome measures based on magnetic resonance imaging (MRI) have been developed and many pitfalls of clinical trials have been identified, resulting in improved experimental methods and more effective interpretation of results.
    [33] Accordingly, another object of the present invention is a method of treating MS by administering an effective amount of a chemokine variant according to the present invention together with a pharmaceutically acceptable excipient.
    [34] "Effective amount" means the amount of active ingredient sufficient to affect the course and severity of such a disease and induce a reduction or alleviation of this pathology. The effective amount depends on the route of administration and the condition of the patient.
    [35] Another object of the present invention is a pharmaceutical composition containing the chemokine variant of the present invention in the presence of one or a plurality of pharmaceutically acceptable excipients for the treatment of MS and / or other demyelinating diseases.
    [36] "Pharmaceutically acceptable" is intended to include any carrier which does not interfere with the biological efficacy of the active ingredient and which does not cause toxicity to the administered subject. For example, for intestinal administration, the active ingredient may be prepared in unit dosage forms for injection in liquid form such as saline, dextrose solution, serum albumin, Ringer's solution.
    [37] In addition to the pharmaceutically acceptable carrier, the compositions of the present invention may further contain small amounts of additives such as stabilizers, excipients, buffers, preservatives.
    [38] Such active ingredients may be administered intravenously, intramuscularly or subcutaneously. Other routes of administration that can establish the blood levels of the individual components to desired levels are also included in the present invention.
    [39] The optimal dose of the active ingredient may be appropriately selected depending on the route of administration, the patient's condition and characteristics (age, sex, weight, health, size), degree of symptom, relapse treatment, frequency of treatment, and desired effect. Adjustments and treatments of established dose ranges are within the capabilities of those skilled in the art.
    [40] In general, the daily dose of the active ingredient is approximately 0.01 to 100 mg / kg body weight. Typically, 1-40 mg / kg daily given in divided portions or sustained release form is effective to achieve the desired result. Secondary or subsequent administration may be at a dose that is less than, or more than, the same as the dose initially or previously administered to the individual.
    [41] Although the present invention has been described with reference to specific embodiments, the present invention includes all modifications made by those skilled in the art without departing from the spirit and object of the claims.
    [42] The invention is illustrated by the following examples, which in no way limit the invention. Examples refer to the drawings specified below.
    [54] 1. Materials and Methods
    [55] a) production of non-heparin-binding RANTES variants
    [56] Mutagenesis of RANTES is achieved by reverse transcription chain reaction technology. Point mutations are introduced into one of two primers used to hybridize with the human RANTES coding sequence (GenBank acc. No. NM — 002985) in the opposite direction. To increase the efficiency of primer annealing (particularly when multiple mutations are introduced into the primer), the DNA is alkali-denatured. Denatured DNA is diluted to a concentration of approximately 10 pg / reaction so that unmuted DNA does not participate in the transformation reaction.
    [57] The amino acid numbers set forth in the examples and the detailed description contemplate mature proteins starting with Ser at position 24, according to the sequence listing. Thus, 23 is added to the numbers described in the Examples or the detailed description to fully match the amino acid numbers in the sequence listing and the examples.
    [58] The mutagenic primer sequences used are as follows and the mutated bases are underlined:
    [59] R44A (Sense)
    [60] 5'-TTTGTCACC GC AAAGAACCGCCAAG-3'.P1
    [61] R44A (anti-sense)
    [62] 5'-GACGACTGCTGGGTTGGA GC ACTTG-3'.P2
    [63] K45A (sense)
    [64] 5'-TTTGTCACCCGAGCGAACCGCCAAG-3'.P3
    [65] K45A (anti-sense)
    [66] 5'-GACGACTGCTGGGTTGGAGCACTTG-3'.P4
    [67] R47A (Sense)
    [68] 5'-CGAAAGAAC GC CCAAGTGTGTGCCA-3'.P5
    [69] R47A (anti-sense)
    [70] 5'-GGTGACAAAGACGACTGCTGGGTTG-3'.P6
    [71] R44A-K45A-R47A (triple 40 'variant, sense)
    [72] 5'-TTTGTCACC GC A GC GAAC GC CCAAGTGTGTGCCAAC-3'.P7
    [73] R44A-K45A-R47A (triple 40 'variant, anti-sense)
    [74] 5'-GACGACTGCTGGGTTGGAGCACTTGCC-3.P8
    [75] K55A (Sense)
    [76] 5'-GCCAACCCAGAG GC GAAATGGGTTCGG-3'.P9
    [77] K55A (anti-sense)
    [78] 5'-ACACACTTGGCGGTTCTTTCGGGTGAC-3'.P10
    [79] K56A (sense)
    [80] 5'-AACCCAGAGAAG GC ATGGGTTCGGGAG-3.P11
    [81] K56A (anti-sense)
    [82] 5'-GGCACACACTTGGCGGTTCTTTCGGGT-3'.P12
    [83] R59A (Sense)
    [84] 5'-AAGAAATGGGTT GC GGAGTACATCAAC-3'.P13
    [85] R59A (anti-sense)
    [86] 5'-CTCTGGGTTGGCACACACTTGGCG-3'.P14
    [87] K55A-K56A-R59A (Triple 50 'variant, sense)
    [88] 5'-GCCAACCCAGAG GC G GC ATGGGTT GC GGAGTACATC-3'P15
    [89] K55A-K56A-R59A (Triple 50 'variant, anti-sense)
    [90] 5'-ACACACTTGGCGGTTCTTTCGGGTGACAAAGAC-3'.P16
    [91] Amplification using pfuturbo ® DNA polymerase (Strategene) is performed 35 times in DNA gene amplifier (Perkin-Elmer-Cetus 480) . DNA was then ligated and transformed into Top 10F 'comb impedance agent coli (E. coli) cells (Invitrogen). The sequence of the variant is verified by DNA sequencing.
    [92] b) Escherichia coli ( E. coliExpression and Purification of Wild-type (WT) RANTES and RANTES Variant
    [93] DNA fragments obtained by PCR as described above are cloned into plasmid pET24d (FIG. 2) to generate a series of vectors. WT or mutated RANTES coding sequence is cloned between the Xbal and Nhel / Xhol sites in the pT7 promoter. The plasmid has two marker genes (Km and lacl) and one active origin of replication (Ori fl).
    [94] The resulting vectors are used to retransform the BL21 (DE3) E. coli strain, which allows for strong protein expression using the pT7 / Lacl system. Protein expression is induced by adding 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) to the culture. Cells were harvested and lysis buffer (50 mM Tris-HCl pH 8, 10 mM MgCl 2 , 5 mM benzamidine / HCl, 1 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), DNase 20 mg / l) Resuspend in. Cells are broken through three passes through a French Press Cell unit. The suspension is then centrifuged at 10,000 xg for 30 minutes at 4 ° C. Inclusion body pellets containing either WT RANTES or RANTES variant are dissolved in 0.1M Tris / HCl, pH 8.0 and 1 mM DTT containing 6M guanidine / HCl and stirred at 60 ° C. for 30 minutes. The solution is dialyzed against 1% acetic acid exchanged three times. Insoluble material is removed by centrifugation at 10,000 xg for 30 minutes. Supernatants bearing either WT RANTES or RANTES variant are lyophilized.
    [95] Lyophilized powder was dissolved in 0.1M Tris / HCl, pH 8.0 and 1 mM DTT containing 6M guanidine / HCl to achieve a concentration of approximately 1 mg / ml. Proteins are regenerated by dropwise dilution with a 10 × volume of 20 mM Tris / HCl, pH 8.0 solution containing 0.01 mM oxidized glutathione and 0.1 mM reduced glutathione. The solution is stirred at 4 ° C. overnight. Insoluble material is removed by centrifugation at 10,000 x g for 30 minutes. The pH is adjusted to 4.5 with acetic acid and the conductivity is adjusted to 20 mS by dilution with water. The solution is passed through a Hiload S 26/10 column pre-equilibrated at 20 mM sodium acetate, pH 4.5, and the protein is eluted with a linear 0-2M NaCl concentration gradient in the same buffer. Aliquots containing either WT RANTES or RANTES variant protein are collected, dialyzed in 3% exchanged 1% acetic acid and lyophilized.
    [96] Lyophilized protein is dissolved in 50 mM Tris / HCl, pH 8.0. The MKKKWPR leader sequence derived from the cloning process is incubated with endoproteinase Arg-C (1: 600 enzyme: substrate, w / w) at 37 ° C. overnight and cleaved from either WT RANTES or RANTES variant protein. The cleaved protein was isolated from the protein which was not cleaved by cation exchange chromatography on a Hiload S 26/10 column pre-equilibrated at 20 mM sodium acetate, pH 4.5 containing 6M urea, and the protein was linear 0-2M NaCl in the same buffer. Elute with a concentration gradient. Cleaved aliquots are collected, dialyzed twice in 1% acetic acid and finally 0.1% trifluoroacetic acid and lyophilized (Edgerton MD et al., Pg. 33-40; Proudfoot AE et al., Pg. 75- 87, in "Chemokine Protocols", Methods in Molecular Biology 2000, vol. 138, uman Press).
    [97] The authenticity of WT and RANTES variant proteins is verified by mass spectroscopy. In a similar process, other variants carrying Met with NH 2 -terminal extension and single or triple 40 'RANTES variants and single or triple 50' variants were made.
    [98] c) Peachia Stories ( Pichia pastorisExpression and Purification of Wild-type (WT) RANTES and RANTES Variant
    [99] Mature triple 40 'RANTES variants (R44A-K45A-R47A) are produced by megaprimer based PCR mutagenesis (Datta AK, Nucleic Acid Research 1995, 23 (21): 4530-31). This is cloned into the Pichia pastoris expression vector, pPIC9K, of the Saccharomyces cerevisiae Mat alpha pre-pro signal peptide backbone.
    [100] After sequence identification, the plasmid is transformed into Pichia pastoris host strain GS115 ( his4 ) by electroporation. His + clones screen expression of RANTES variants. Small-scale expression studies are conducted using standard procedures outlined in Invitrogen (Life Technologies) Pichia Expression Kit. In brief, the culture is expanded in enriched medium using glycerol as a carbon source, then pelleted and resuspended in medium containing methanol to induce the expression of RANTES variant protein. Secretion of the RANTES variant in the medium is detected on Coomassie blue stained SDS-PAGE.
    [101] Clones that secrete high levels of RANTES variants (approximately 500-750 mg / l) are used for scale up in large shake flasks. The fermented liquid medium is centrifuged at 5,000 rpm and the supernatant used for purification.
    [102] Proteins are purified from supernatants in a single chromatography step on a Heparin Sepharose column equilibrated in 0.1 M Tris-HCl and eluted with a linear gradient of 0-2 M Nacl in the same buffer using 20 column volumes. The authenticity of the protein is verified by mass spectroscopy, and the RANTES variant (R44A-K45A-R47A) thus made in this system was also found to lack the first two amino acids at the N-terminus compared to the wild type molecule. Thus, the variant thus obtained was identified as triple 40 'RANTES (3-68), whose amino acid sequence is SEQ ID NO: 3 sequence.
    [103] d) heparin binding assay
    [104] Heparin Sepharose Chromatography was performed using 50 μg WT or mutated RANTES protein, which was loaded onto a Heparin Sepharose column equilibrated at 25 mM Tris / HCl, pH 8.0, 25 mM Tris / HCl, pH 8.0 Elute with a linear gradient of 0-2 M NaCl at.
    [105] Heparin Sepharose chromatography is performed using 50 μg WT or mutated RANTES protein, which is loaded onto a MonoS cation exchange column equilibrated at 50 mM sodium acetate, pH 4.5. Protein is eluted with 0-2M Nacl concentration gradient.
    [106] Competitive binding assays revealed WT RANTES, triple 50 'RANTES variant, triple 40' RANTES variant radiolabeled to 125 I by Amersham with a specific activity of 2200 mCi / mole (SEQ ID NO: 2-"R44A-K45A-R47ARANTES" Is carried out using). Filter plates with 96 wells are soaked in binding buffer (1 mM CaCl 2 , 5 mM MgCl 2 , 0.15 M NaCl, 50 mM HEPES with 0.5% BSA, pH 7.2). Serial dilution of heparin in binding buffer is carried out in a concentration range of 20 mg / ml to 1 μg / ml. Assays are run in a total volume of 100 μl by adding 25 μl heparin dilution, 25 μl 0.4 nM [ 125 I] -chemokine, 25 μl heparin beads (0.2 μg / ml in water), 25 μl binding buffer. This analysis is repeated three times. Plates are incubated for 4 hours at room temperature with shaking. The filter plate is washed three times with 200 μl wash buffer using a vacuum pump to remove unbound labeled chemokines. 50 μl scintillant is then added to each well and radioactivity is measured (1 min / well). Data is analyzed with GraFit software.
    [107] e) Equilibrium contention receptor binding assay
    [108] This analysis is performed on membranes obtained from CHO transfectants expressing CCR1 or CCR5 by [SPA] using [ 125 I] -MIP-1α as a probe. The competition is prepared by diluting the unlabeled chemokines in the binding buffer in the range of 10 -6 -10 -12 M. The binding buffer used was 50 mM HEPES, pH 7.2, containing 1 mM CaCl 2 , 5 mM MgCl 2 , 0.15 M NaCl, 0.5% BSA. Wheatgerm SPA beads (Amersham) were dissolved at 50 mg / ml in PBS and diluted to 10 mg / ml in binding buffer with a final concentration of 0.25 mg / well in this assay. Membranes prepared from CHO1 expressing CCR1 or CCR5 are stored at -80 ° C and diluted to 80 μg / ml in binding buffer. Each dose of membrane and bead stock is mixed prior to conducting the assay to reduce background. The final membrane concentration is 2 μg / ml and the final concentration of [ 125 I] -MIP-1α is 0.1 nM. Plates are incubated for 4 hours at room temperature with shaking. Radioactivity is measured and data analyzed as revealed in the heparin-binding assay.
    [109] f) chemotaxis analysis
    [110] Monocyte chemotaxis is performed by micro-boyden chamber analysis. Monocytes are purified from the buffy coat using the following separation procedure: 100 ml leukocyte layer solution is diluted with 100 ml PBS, layered in picol and centrifuged at 600 xg for 20 minutes at room temperature. The cells forming the interface were harvested, washed twice with PBS and 40-100 × 10 6 / in RPMI 1640 medium containing 5% inactivated fetal bovine serum (FCS), 2 mM glutamine, 25 mM HEPES, pH 7.2. Resuspend in ml. They are further purified from lymphocyte aliquots by addition of 10 6 sheep erythrocytes / ml and re-separated overnight at 4 ° C. and separated by secondary picol gradient centrifugation at 900 × g for 20 min at room temperature. Monocytes are found at the interface between Ficoll and buffer, and T cells are present in the pellets. Monocytes are washed in PBS and resuspended at 2.5 × 10 6 / ml in RPMI 1640 medium. Purity was measured by FACS analysis with forward and lateral scattering, which was found to depend on donors 40-80%. Chemokines are diluted to a final volume of 30 μl and the concentration range of 10 −6 −10 −12 M in RPMI medium is placed in the lower wells. A filter (Neuroprobe) with a 5 μm pore size for monocytes and an 8 μm pore size for T cells is placed in the bottom well to ensure that the system is sealed without the presence of air bubbles. 50 ml cell suspension (2.5 × 10 6 cells / ml) dissolved in RPMI medium is placed in the upper wells. The chamber is incubated under O 2 at 37 ° C. for 30 minutes for monocytes and 1.5 hours for T cells. The cells are then discarded, the upper surface of the membrane is scrubbed to remove the cells, and the membrane is washed with PBS. The membrane is fixed by immersion in MeOH for 1 minute, air dried and stained with Field A and B solutions. The migrated cells are counted by selecting random fields for each well at 20 × magnification on a standard microscope with IBAS image analysis software. Data is merged with GraFit software.
    [111] g) peritoneal cell mobilization assay
    [112] In the first assay, cell recruitment is induced by intraperitoneal injection of 10 μg chemokine diluted in 0.2-ml sterile saline (LPS-free Nacl) in 8 to 12 week old female BALB / c mice. Chemokine variants (10 μg chemokine diluted in 0.2 ml sterile saline) are administered 30 minutes prior to administration of the agonist. After 16 hours, mice are sacrificed with aerosolized CO 2 . Abdominal lavage is performed three times with 5 ml PBS, and the lavage fluid is collected. Cells are centrifuged at 600 × g for 10 minutes and resuspended in 1 ml final volume and total leukocytes counted with a hemocytometer.
    [113] In a second assay, cell recruitment is induced by intraperitoneal injection of 200 μl of 3% thioglycolate solution dissolved in sterile water in 8-12 week old female BALB / c mice (day 1). Chemokine variants (10 μg chemokine diluted in 0.2 ml sterile saline) are administered 30 minutes prior to thioglycolate administration. Chemokine variants are administered daily for 3 days (2 days, 3 days, 4 days). Mice are sacrificed with aerosolized CO 2 on day 5. Abdominal lavage is performed three times with 5 ml PBS, and the washings are collected. Cells are centrifuged at 600 × g for 10 minutes and resuspended in 1 ml final volume and total leukocytes counted with a hemocytometer.
    [114] h) experimental autoimmune encephalomyelitis (EAE)
    [115] Immunization Process
    [116] 18-22 g 8-week-old C57 BL / 6NCrlBR female mice were given a complete Freund's adjuvant (CFA, Difco, Detriot, USA) containing 0.25 mg Mycobacterium tuberculosis ( Mycobacterium butyricum ) the 200 ㎍ MOG dissolved in 35 - 55 peptide (Neosystem, Strasbourg, France) with 0.1 ㎖ emulsion is immune to later sc injection in the neck containing a. Prior to sc injection, they inject 200 μl iv into the tail vein with 300 ng pertussis toxin dissolved in PBS. On day 2, these animals receive a second ip injection of 300 ng pertussis toxin.
    [117] This process leads to progressive paralysis, beginning at approximately 8-10 days and gradually from the tail to the forelimbs.
    [118] Study design
    [119] In this study, each group consisted of 10 animals. Any group according to the immunization protocol, a 35 MOG dissolved in CFA - is immunized with 55 peptide and pertussis toxin.
    [120] Group 1: i.p. Positive control administered vehicle alone (PBS) as route
    [121] Group 2: s.c. Positive control administered vehicle alone (PBS) as route
    [122] Group 3: i.p. of 10 μg / mouse triple 40 ′ RANTES variant. administration
    [123] Group 4: i.p. of 1 μg / mouse triple 40 ′ RANTES variant. administration
    [124] Group 5: i.p. of 10 μg / mouse triple 40 ′ Met-RANTES variant. administration
    [125] Group 6: i.p. of 1 μg / mouse triple 40 ′ Met-RANTES variant. administration
    [126] Group 7: s.c. of 10,000 U / mouse mouse recombinant interferon beta (m-IFN-β). administration
    [127] Group 8: s.c. of 20,000 U / mouse m-IFN-β. administration
    [128] Carrier
    [129] PBS is used to dilute RANTES 40 'triple variant, Met-RANTES 40' triple variant, mIFN-β to appropriate concentrations.
    [130] Dosing route
    [131] Triple 40 'RANTES variant, triple 40' Met-RANTES variant, m-IFN-β was administered daily at i.p. Administration. Groups 1 and 2 were 200 μl / mouse PBS in i.p. Administration.
    [132] Treatment period
    [133] Treatment begins on day 4 of the experiment (approximately 3-5 days before onset) and lasts for 14 days (sacrifice of animals on day 18 of experiment).
    [134] Clinical observation
    [135] Beginning on day 5, all animals are individually examined for the presence of paralysis with the following clinical scores:
    [136] 0 = no signs of illness
    [137] 0.5 = partial tail paralysis
    [138] 1 = tail paralysis
    [139] 1.5 = tail paralysis + partial hind limb paralysis
    [140] 2 = tail paralysis + weakness or partial paralysis of the hind legs
    [141] 2.5 = tail paralysis + partial hind limb paralysis (sagging pelvis)
    [142] 3 = tail paralysis + complete hind limb paralysis
    [143] 3.5 = Tail Paralysis + Complete Hind Limb + Incontinence
    [144] 4 = tail paralysis + hind limb paralysis + weakness or partial paralysis of the forelimb
    [145] 5 = death
    [146] 2. Results
    [147] a) heparin binding assay
    [148] Purified RANTES proteins mutated at one or three positions are analyzed by heparin chromatography and the concentration of NaCl required to elute them is compared with the elution profile of WT RANTES. Since the interaction with heparin is electrostatic, these variants are also subjected to cation exchange chromatography on a MonoS column. This results in a decrease in the NaCl concentrations required to elute them, because such mutagenesis removes basic residues. The difference in NaCl concentration obtained in cation exchange chromatography is subtracted from the difference in concentration obtained in heparin chromatography. If this value is positive, there is a specific interaction with heparin (Table 1).
    [149] The binding to heparin is measured directly in triple 40 'and 50' RANTES variants during the competitive binding assay. WT RANTES and the variant were iodinated with Amersham, both of which possessed the same specific radioactivity of 2,200 mCi / mole. However, only 20% of the triple 40 'variant binds to heparin beads and the maximum cpm value is 4,000 cpm compared to 20,000 cpm of WT RANTES and 50' variant. This demonstrates that these residues contribute significantly to the heparin binding capacity of RANTES in the mutated 40 'loop. On the other hand, this demonstrates that the putative GAG-binding motif in the 50 'loop is not a "true" GAG-binding site.
    [150] b) Equilibrium contention receptor binding assay
    [151] The ability of triple 40 'and triple 50' RANTES variants to compete with [ 125 I] MIP-1α for binding to recombinant CCR1 and CCR5 in membranes prepared from CHO stable transfectants is analyzed. There was no significant difference between single mutations at both receptors. The triple variant showed no difference in binding with CCR5 compared to the WT RANTES protein. However, triple 40 ′ variants in CCR1 showed a 100-fold reduction in affinity, while triple 50 ′ variants showed a small (3-fold) decrease in affinity (FIG. 4).
    [152] c) chemotaxis analysis
    [153] The triple 40 'and 50' variants were able to induce monocyte chemotaxis with activity comparable to WT RANTES except for the triple 40 'variant which could induce significant chemotaxis only at 1 μM. However, triple 40 'and 50' variants were equivalent in their ability to induce T cell chemotaxis (FIG. 5).
    [154] The results from monocyte chemotaxis assays are consistent with those from receptor binding assays. The loss of activity of the triple 40 'RANTES variant for monocyte chemotaxis is consistent with the loss of affinity for CCR1.
    [155] d) Peritoneal Cell Mobilization Assay
    [156] Triple 40 'RANTES variants could not induce cell recruitment to the peritoneum at doses (10 μg / mouse) where RANTES elicited substantial recruitment.
    [157] In addition, cell recruitment induced by RANTES was inhibited when 10 μg variants were administered 30 minutes prior to RANTES administration. Thus, disruption of GAG-binding resulted in inhibitors of chemokine-induced cell recruitment in vivo.
    [158] Truncated RANTES (3-68) triple 40 'variant (produced by Pichia pastoris ), MIP-1β triple 40' variant (K45A-R46A-K48A), MIP-1α triple 40 'variant (R18A- Similar results obtained in R46A-K48A) are shown in FIGS. 7,8,9, respectively. As shown in FIG. 10, cell recruitment promoted by thioglycolate was also inhibited by the triple 40 ′ RANTES variant.
    [159] e) experimental autoimmune encephalomyelitis (EAE)
    [160] Triple 40 'RANTES variant showed a dose-related effect in the murine EAE model. The protein was MOG and 1 μg and 10 μg / mouse i.p. When administered, it showed efficacy comparable to the reference therapeutic, recombinant m-IFN-β (FIG. 11). The onset of the disease was significantly delayed and disease severity (assessed by the area under the curve) was also significantly reduced. In addition, the average of the maximum clinical scores reached during the experiment decreased. Other variants (triple 40 ′ Met-RANTES variants) did not show a beneficial effect in the same experiment.
    [161] These results demonstrate the beneficial effect of treatment with 40 'RANTES triple variant, which reduces the clinical signs of chronic EAE in mice after MOG immunization. Thus, the triple 40 'RANTES variant has a beneficial therapeutic effect and can be used as a therapeutic drug in chronic demyelinating diseases such as MS.
    [162] Table 1. NaCl molarity for elution from heparin and Mono-S (cationic exchange) columns
    [163] RANTES mutationHeparinMonoSΔNaCl Hep-S △ NaCl Monoe-S △△ NaCl No (WT)0.800.91------------------ R44A0.610.820.190.090.10 K45A0.650.970.150.040.11 R47A0.650.840.150.070.08 R44A-K45A-R47A0.470.700.330.210.11 K55A0.700.860.100.05-0.05 K56A0.900.94-0.100.07-0.17 R59A0.790.850.010.06-0.05 K55A-K56A-R59A0.700.750.100.16-0.06
    [164] Table 2 below clearly illustrates the nature of the sequences reported in the sequence listing and throughout the specification.
    [165] SEQ ID NO:Sequence description OneWild type (WT) RANTES 2Triple 40 'RANTES Variant 3Triple 40 'RANTES (3-68) Variant 4Triple MIP-1-alpha Variants (R18A-R46A-R48A) 5Triple MIP-1-beta variants (K45A-R46A-K48A) 6Triple 50 'RANTES Variant 7Triple 40 'Met-RANTES Variant 8R44A-RANTES Variant 9K45A-RANTES Variant 10K47A-RANTES Variant 11K55A-RANTES Variants 12K56A-RANTES Variant 13K59A-RANTES Variant 14Primer P1 15Primer P2 16Primer P3 17Primer P4 18Primer P5 19Primer P6 20Primer P7 21Primer P8 22Primer P9 23Primer P10 24Primer P11 25Primer P12 26Primer P13 27Primer P14 28Primer P15 29Primer P16 30WT-1309 31WT-MIP-1-alpha 32WT-MIP-1-beta 33WT-MIP-4 34WT-MIP-5 35WT-HCC1 36WT-I36512 37WT-MCP-2
    权利要求:
    Claims (14)
    [1" claim-type="Currently amended] Pharmaceuticals for the treatment of multiple sclerosis or other demyelinating diseases, in the use of CC chemokine variants having at least two mutations in the cationic site of the 40 'loop and exhibiting reduced GAG-binding activity compared to wild-type molecules. Used in the manufacture of a composition, wherein said CC chemokine is selected from RANTES, MIP-1 alpha, MIP-1 beta, MIP-3, MIP-4, HCC1, I309, I35612, MCP-2.
    [2" claim-type="Currently amended] The method of claim 1, wherein the chemokine variant is a RANTES variant.
    [3" claim-type="Currently amended] 3. Use according to claim 2, wherein the chemokine variant is a RANTES triple variant, wherein at the cationic portion of the 40 'loop the three basic amino acids are substituted with other amino acids.
    [4" claim-type="Currently amended] 4. Use according to claim 3, wherein at the cationic portion of the 40 'loop the three basic amino acids are substituted with alanine, serine, threonine, proline or glycine.
    [5" claim-type="Currently amended] The method of claim 1, wherein the chemokine variant is mutated RANTES of SEQ ID NO: 3.
    [6" claim-type="Currently amended] The method of claim 1, wherein the chemokine variant is a RANTES variant of SEQ ID NO: 2.
    [7" claim-type="Currently amended] The method of claim 1, wherein the chemokine variant is a MIP-1-alpha variant of SEQ ID NO: 4.
    [8" claim-type="Currently amended] The method of claim 1, wherein the chemokine variant is a MIP-1-beta variant of SEQ ID NO: 5.
    [9" claim-type="Currently amended] A pharmaceutical composition for the treatment of multiple sclerosis or other demyelinating diseases, wherein the pharmaceutical composition comprises a chemokine variant according to any one of claims 1 to 8 together with a pharmaceutically acceptable excipient as an active ingredient. Pharmaceutical composition.
    [10" claim-type="Currently amended] Truncated and mutated human RANTES having the amino acid sequence of SEQ ID NO: 2.
    [11" claim-type="Currently amended] A DNA molecule comprising a DNA sequence encoding the truncated and mutated RANTES of claim 10.
    [12" claim-type="Currently amended] An expression vector comprising the DNA molecule of claim 11.
    [13" claim-type="Currently amended] A host cell comprising the expression vector of claim 12.
    [14" claim-type="Currently amended] Recombinant process for preparing the polypeptide of claim 10, wherein the cell of claim 13 is cultivated in a suitable culture medium.
    类似技术:
    公开号 | 公开日 | 专利标题
    Borthwick2016|The IL-1 cytokine family and its role in inflammation and fibrosis in the lung
    Bozic et al.1995|Expression and biologic characterization of the murine chemokine KC.
    Rankin et al.2000|Eotaxin and eosinophil recruitment: implications for human disease
    Garcia-Zepeda et al.1996|Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia
    Liekens et al.2010|CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization
    Shanley et al.1995|Role of macrophage inflammatory protein-1 alpha | in acute lung injury in rats.
    Gough et al.1988|Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor
    Schulz-Knappe et al.1996|HCC-1, a novel chemokine from human plasma.
    EP1071449B1|2006-09-06|Use of an antagonist antibody to the inflammatory mediator oncostatin m |
    JP3677288B2|2005-07-27|Macrophage inflammatory protein-3, -4 and -1 [lower γ]
    KR100234520B1|1999-12-15|Pharmaceutical composition for treating tumor necrosis factor mediated diseases
    Rothenberg et al.1995|Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression
    TW593336B|2004-06-21|Low-toxicity human interferon-alpha analog
    US6734168B2|2004-05-11|Endothelial monocyte activating polypeptide II: a mediator which activates host response
    JP3705732B2|2005-10-12|Novel polypeptide, production method thereof, DNA encoding the polypeptide, vector comprising the DNA, host cell transformed with the vector
    DE69017753T3|2013-06-20|Tumor necrosis factor binding protein II, its purification and specific antibodies
    KR100223255B1|1999-10-15|Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
    DE69520088T3|2006-11-23|Interferon gamma-inducing polypeptide monoclonal antibody, and composition for interferon-gamma bound diseases
    US6184359B1|2001-02-06|Antibodies to epithelium-derived T-cell factor
    US5776892A|1998-07-07|Anti-inflammatory peptides
    US5359032A|1994-10-25|Interkeukin-1 inhibitor
    US7999067B2|2011-08-16|Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
    JP5351078B2|2013-11-27|Compositions and methods for inhibiting or enhancing inflammatory responses
    AU2004281552B2|2009-10-22|Therapeutic uses of chemokine variants
    KR101188785B1|2012-10-16|Gag binding proteins
    同族专利:
    公开号 | 公开日
    RS50738B|2010-08-31|
    CZ2003947A3|2003-11-12|
    MXPA03003008A|2003-07-14|
    US20040101509A1|2004-05-27|
    AT265222T|2004-05-15|
    CA2423616A1|2002-04-11|
    HU0302194A3|2005-12-28|
    AR030854A1|2003-09-03|
    WO2002028419A2|2002-04-11|
    PL204231B1|2009-12-31|
    KR100837898B1|2008-06-13|
    JP2004510426A|2004-04-08|
    DK1326628T3|2004-08-09|
    PT1326628E|2004-09-30|
    BG107685A|2003-11-28|
    ES2217199T3|2004-11-01|
    SK287523B6|2011-01-04|
    HU0302194A2|2003-10-28|
    EP1326628A2|2003-07-16|
    HRP20030215B1|2011-09-30|
    JP3908165B2|2007-04-25|
    EE200300139A|2003-06-16|
    NO20031525L|2003-04-03|
    HRP20030215A2|2005-02-28|
    WO2002028419A3|2002-06-13|
    EP1326628B1|2004-04-28|
    HK1062811A1|2007-03-02|
    SI1326628T1|2004-10-31|
    SK4062003A3|2003-08-05|
    CA2423616C|2010-03-16|
    BG66137B1|2011-07-29|
    EE05174B1|2009-06-15|
    DE60103078T2|2005-04-07|
    BR0114407A|2003-07-29|
    US7402303B2|2008-07-22|
    DE60103078D1|2004-06-03|
    CN1285381C|2006-11-22|
    EA200300439A1|2003-08-28|
    NO330278B1|2011-03-21|
    IL155178D0|2003-11-23|
    YU25703A|2006-05-25|
    ZA200302315B|2004-03-25|
    AU2002215919B2|2005-11-24|
    CZ303409B6|2012-09-05|
    EA006137B1|2005-10-27|
    AU1591902A|2002-04-15|
    IL155178A|2009-07-20|
    NO20031525D0|2003-04-03|
    UA77950C2|2007-02-15|
    PL362350A1|2004-10-18|
    CN1477969A|2004-02-25|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-10-04|Priority to EP00121665.4
    2000-10-04|Priority to EP00121665
    2001-10-03|Application filed by 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.
    2001-10-03|Priority to PCT/EP2001/011428
    2003-05-01|Publication of KR20030034238A
    2008-06-13|Application granted
    2008-06-13|Publication of KR100837898B1
    优先权:
    申请号 | 申请日 | 专利标题
    EP00121665.4|2000-10-04|
    EP00121665|2000-10-04|
    PCT/EP2001/011428|WO2002028419A2|2000-10-04|2001-10-03|Chemokine mutants in the treatment of multiple sclerosis|
    [返回顶部]